The Latin America, Middle East and Africa Age Related Macular Degeneration (AMD) Market would witness market growth of 9.2% CAGR during the forecast period (2023-2030).
With the rising number of products approved for treating wet AMD, the market for is anticipated to rise. For instance, Roche said that the FDA had authorized Susvimo (ranibizumab injection) 100 mg/mL for intravitreal use through an ocular implant to treat persons with neovascular or wet age-related macular degeneration (AMD) in October 2021.
To fill the healthcare gap, many pharmaceutical companies are actively competing in the market. Many pharmaceutical companies are currently focusing on treatments for age-related macular degeneration (AMD), and there are more than ten such medications in various phases of research.
The International Trade Administration estimates Saudi Arabia will spend $36.8 billion on healthcare and social development in 2022, accounting for 14.4% of its total budget. The privatization of the healthcare industry is a goal of the Saudi Arabian government. As part of Vision 2030, the Saudi Arabian government has allocated roughly $65 billion to the development of the healthcare sector.
Additionally, it intends to privatize 290 hospitals and 2,300 primary health centers by 2030, increasing private sector participation from 40% to 65%. With a 9.1% GDP expenditure on healthcare, Brazil has the largest healthcare sector in Latin America. 63% of the 6,642 hospitals in Brazil are private, 532,645 hospital beds, 88,000 healthcare support services, 502,000 doctors, 331,000 dentists, and 89,000 drugstores are all present as of 2021. At least 70% of the Brazilian population receives primary healthcare from the country's Unified Healthcare System (SUS). Also, the government of UAE aims to make the region a hub for medical tourism. The market is predicted to expand in this region due to growing healthcare infrastructure and government spending.
The Brazil market dominated the LAMEA Age Related Macular Degeneration (AMD) Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $198.6 million by 2030. The Argentina market is showcasing a CAGR of 9.8% during (2023 - 2030). Additionally, The UAE market would register a CAGR of 8.9% during (2023 - 2030).
Based on Drug Type, the market is segmented into Aflibercept, Ranibizumab and Others. Based on Disease Type, the market is segmented into Wet and Dry. Based on Distribution Channel, the market is segmented into Hospital Pharmacy, Retail Pharmacy and Online Pharmacy. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Worldwide Age Related Macular Degeneration (AMD) Market is Projected to reach USD 13.9 Billion by 2030, at a CAGR of 5.4%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Biogen, Inc., Bayer AG, Apellis Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ionis Pharmaceuticals, Inc., Novartis AG, Sanofi S.A., Coherus Biosciences, Inc. and Bausch Health Companies, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Drug Type
- Aflibercept
- Ranibizumab
- Others
By Disease Type
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Biogen, Inc.
- Bayer AG
- Apellis Pharmaceuticals, Inc.
- Regeneron Pharmaceuticals, Inc.
- F.Hoffmann-La Roche Ltd.
- Ionis Pharmaceuticals, Inc.
- Novartis AG
- Sanofi S.A.
- Coherus Biosciences, Inc.
- Bausch Health Companies, Inc.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 LAMEA Age Related Macular Degeneration (AMD) Market, by Drug Type
1.4.2 LAMEA Age Related Macular Degeneration (AMD) Market, by Disease Type
1.4.3 LAMEA Age Related Macular Degeneration (AMD) Market, by Distribution Channel
1.4.4 LAMEA Age Related Macular Degeneration (AMD) Market, by Country
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
3.3 Porter Five Forces Analysis
Chapter 4. Strategies deployed in Age Related Macular Degeneration (AMD) Market
Chapter 5. LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type
5.1 LAMEA Aflibercept Market by Country
5.2 LAMEA Ranibizumab Market by Country
5.3 LAMEA Others Market by Country
Chapter 6. LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type
6.1 LAMEA Wet Market by Country
6.2 LAMEA Dry Market by Country
Chapter 7. LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel
7.1 LAMEA Hospital Pharmacy Market by Country
7.2 LAMEA Retail Pharmacy Market by Country
7.3 LAMEA Online Pharmacy Market by Country
Chapter 8. LAMEA Age Related Macular Degeneration (AMD) Market by Country
8.1 Brazil Age Related Macular Degeneration (AMD) Market
8.1.1 Brazil Age Related Macular Degeneration (AMD) Market by Drug Type
8.1.2 Brazil Age Related Macular Degeneration (AMD) Market by Disease Type
8.1.3 Brazil Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.2 Argentina Age Related Macular Degeneration (AMD) Market
8.2.1 Argentina Age Related Macular Degeneration (AMD) Market by Drug Type
8.2.2 Argentina Age Related Macular Degeneration (AMD) Market by Disease Type
8.2.3 Argentina Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.3 UAE Age Related Macular Degeneration (AMD) Market
8.3.1 UAE Age Related Macular Degeneration (AMD) Market by Drug Type
8.3.2 UAE Age Related Macular Degeneration (AMD) Market by Disease Type
8.3.3 UAE Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.4 Saudi Arabia Age Related Macular Degeneration (AMD) Market
8.4.1 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Drug Type
8.4.2 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Disease Type
8.4.3 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.5 South Africa Age Related Macular Degeneration (AMD) Market
8.5.1 South Africa Age Related Macular Degeneration (AMD) Market by Drug Type
8.5.2 South Africa Age Related Macular Degeneration (AMD) Market by Disease Type
8.5.3 South Africa Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.6 Nigeria Age Related Macular Degeneration (AMD) Market
8.6.1 Nigeria Age Related Macular Degeneration (AMD) Market by Drug Type
8.6.2 Nigeria Age Related Macular Degeneration (AMD) Market by Disease Type
8.6.3 Nigeria Age Related Macular Degeneration (AMD) Market by Distribution Channel
8.7 Rest of LAMEA Age Related Macular Degeneration (AMD) Market
8.7.1 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type
8.7.2 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type
8.7.3 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel
Chapter 9. Company Profiles
9.1 Biogen, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.1.6 SWOT Analysis
9.2 Bayer AG
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 SWOT Analysis
9.3 Apellis Pharmaceuticals, Inc.
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental Analysis
9.3.4 Research & Development Expenses
9.3.5 Recent strategies and developments:
9.3.5.1 Approvals & Trails:
9.3.6 SWOT Analysis
9.4 Regeneron Pharmaceuticals, Inc.
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Research & Development Expense
9.4.4 SWOT Analysis
9.5 F. Hoffmann-La Roche Ltd.
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 SWOT Analysis
9.6 Ionis Pharmaceuticals, Inc.
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Research & Development Expenses
9.6.4 SWOT Analysis
9.7 Novartis AG
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Segmental and Regional Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Approvals & Trails:
9.7.5.2 Acquisition and Mergers:
9.7.6 SWOT Analysis
9.8 Sanofi S.A.
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Segmental and Regional Analysis
9.8.4 Research & Development Expense
9.8.5 SWOT Analysis
9.9 Coherus Biosciences, Inc.
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Research & Development Expenses
9.9.4 Recent strategies and developments:
9.9.4.1 Approvals & Trials:
9.9.5 SWOT Analysis
9.1 Bausch Health Companies, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Segmental and Regional Analysis
9.10.4 Research & Development Expense
9.10.5 Recent strategies and developments:
9.10.5.1 Product Launches and Product Expansions:
9.10.6 SWOT Analysis
TABLE 1 LAMEA Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 2 LAMEA Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 3 LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 4 LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 5 LAMEA Aflibercept Market by Country, 2019 - 2022, USD Million
TABLE 6 LAMEA Aflibercept Market by Country, 2023 - 2030, USD Million
TABLE 7 LAMEA Ranibizumab Market by Country, 2019 - 2022, USD Million
TABLE 8 LAMEA Ranibizumab Market by Country, 2023 - 2030, USD Million
TABLE 9 LAMEA Others Market by Country, 2019 - 2022, USD Million
TABLE 10 LAMEA Others Market by Country, 2023 - 2030, USD Million
TABLE 11 LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 12 LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 13 LAMEA Wet Market by Country, 2019 - 2022, USD Million
TABLE 14 LAMEA Wet Market by Country, 2023 - 2030, USD Million
TABLE 15 LAMEA Dry Market by Country, 2019 - 2022, USD Million
TABLE 16 LAMEA Dry Market by Country, 2023 - 2030, USD Million
TABLE 17 LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 18 LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 19 LAMEA Hospital Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 20 LAMEA Hospital Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 21 LAMEA Retail Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 22 LAMEA Retail Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 23 LAMEA Online Pharmacy Market by Country, 2019 - 2022, USD Million
TABLE 24 LAMEA Online Pharmacy Market by Country, 2023 - 2030, USD Million
TABLE 25 LAMEA Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2022, USD Million
TABLE 26 LAMEA Age Related Macular Degeneration (AMD) Market by Country, 2023 - 2030, USD Million
TABLE 27 Brazil Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 28 Brazil Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 29 Brazil Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 30 Brazil Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 31 Brazil Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 32 Brazil Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 33 Brazil Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 34 Brazil Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 35 Argentina Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 36 Argentina Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 37 Argentina Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 38 Argentina Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 39 Argentina Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 40 Argentina Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 41 Argentina Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 42 Argentina Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 43 UAE Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 44 UAE Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 45 UAE Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 46 UAE Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 47 UAE Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 48 UAE Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 49 UAE Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 50 UAE Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 51 Saudi Arabia Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 52 Saudi Arabia Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 53 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 54 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 55 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 56 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 57 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 58 Saudi Arabia Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 59 South Africa Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 60 South Africa Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 61 South Africa Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 62 South Africa Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 63 South Africa Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 64 South Africa Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 65 South Africa Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 66 South Africa Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 67 Nigeria Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 68 Nigeria Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 69 Nigeria Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 70 Nigeria Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 71 Nigeria Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 72 Nigeria Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 73 Nigeria Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 74 Nigeria Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 75 Rest of LAMEA Age Related Macular Degeneration (AMD) Market, 2019 - 2022, USD Million
TABLE 76 Rest of LAMEA Age Related Macular Degeneration (AMD) Market, 2023 - 2030, USD Million
TABLE 77 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2022, USD Million
TABLE 78 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type, 2023 - 2030, USD Million
TABLE 79 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2022, USD Million
TABLE 80 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type, 2023 - 2030, USD Million
TABLE 81 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2022, USD Million
TABLE 82 Rest of LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2023 - 2030, USD Million
TABLE 83 Key Information – Biogen, Inc.
TABLE 84 Key Information – Bayer AG
TABLE 85 Key Information – Apellis Pharmaceuticals, Inc.
TABLE 86 Key Information – Regeneron Pharmaceuticals, Inc.
TABLE 87 Key Information – F. Hoffmann-La Roche Ltd.
TABLE 88 Key information – Ionis Pharmaceuticals, Inc.
TABLE 89 Key Information – Novartis AG
TABLE 90 Key Information – Sanofi S.A.
TABLE 91 Key Information – Coherus Biosciences, Inc.
TABLE 92 key information – Bausch Health Companies, Inc.
List of Figures
FIG 1 Methodology for the research
FIG 2 LAMEA Age Related Macular Degeneration (AMD) Market, 2019 - 2030, USD Million
FIG 3 Key Factors Impacting Age Related Macular Degeneration (AMD)Market
FIG 4 Porter’s Five Forces Analysis – Age Related Macular Degeneration (AMD) Market
FIG 5 LAMEA Age Related Macular Degeneration (AMD) Market share by Drug Type, 2022
FIG 6 LAMEA Age Related Macular Degeneration (AMD) Market share by Drug Type, 2030
FIG 7 LAMEA Age Related Macular Degeneration (AMD) Market by Drug Type, 2019 - 2030, USD Million
FIG 8 LAMEA Age Related Macular Degeneration (AMD) Market share by Disease Type, 2022
FIG 9 LAMEA Age Related Macular Degeneration (AMD) Market share by Disease Type, 2030
FIG 10 LAMEA Age Related Macular Degeneration (AMD) Market by Disease Type, 2019 - 2030, USD Million
FIG 11 LAMEA Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2022
FIG 12 LAMEA Age Related Macular Degeneration (AMD) Market share by Distribution Channel, 2030
FIG 13 LAMEA Age Related Macular Degeneration (AMD) Market by Distribution Channel, 2019 - 2030, USD Million
FIG 14 LAMEA Age Related Macular Degeneration (AMD) Market share by Country, 2022
FIG 15 LAMEA Age Related Macular Degeneration (AMD) Market share by Country, 2030
FIG 16 LAMEA Age Related Macular Degeneration (AMD) Market by Country, 2019 - 2030, USD Million
FIG 17 Swot Analysis: Biogen, Inc.
FIG 18 Swot Analysis: Bayer AG
FIG 19 Swot Analysis: Apellis Pharmaceuticals, Inc.
FIG 20 Swot Analysis: Regeneron Pharmaceuticals, Inc.
FIG 21 Swot Analysis: F. Hoffmann-La Roche Ltd.
FIG 22 Swot Analysis: Ionis Pharmaceuticals, Inc.
FIG 23 SWOT Analysis: Novartis AG
FIG 24 Swot Analysis: Sanofi S.A.
FIG 25 Swot Analysis: Coherus Biosciences, Inc.
FIG 26 Swot Analysis: Bausch Health Companies, Inc.